Beth Hecht - Mar 20, 2025 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role: Chief Legal Officer and Corporate Secretary
Signature: /s/ Beth Hecht
Stock symbol: XERS
Transactions as of: Mar 20, 2025
Transactions value $: -$217,244
Form type: 4
Date filed: 3/21/2025, 05:31 PM
Previous filing: Feb 3, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XERS	Common Stock	Sale	-$217K	-40K	-2.87%	$5.43	1.35M	Mar 20, 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.380 to $5.475, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.380 to $5.475, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

Chief Legal Officer and Corporate Secretary